Kadriye Baskurt, Medical Oncologist at Etlik City Hospital, shared on X:
“Breaking NCCN Update (v3.2025)
- FLOT remains Cat.1 standard for resectable gastric/GEJ adenocarcinoma
- Durvalumab + FLOT → now Cat.1 option for PD-L1 CPS ≥1 or TAP ≥1 tumors
- PD-L1 testing recommended universally, not only in advanced disease
- Supported by MATTERHORN trial, demonstrating significant EFS benefit
A new era in perioperative gastric cancer management.”
